Oppenheimer Comments on Syros Pharmaceuticals’ Q1 2018 Earnings (SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) – Analysts at Oppenheimer issued their Q1 2018 earnings per share (EPS) estimates for shares of Syros Pharmaceuticals in a research report issued to clients and investors on Monday, March 12th, according to Zacks Investment Research. Oppenheimer analyst L. Cann expects that the company will post earnings per share of ($0.17) for the quarter. Oppenheimer currently has a “Buy” rating and a $28.00 price target on the stock. Oppenheimer also issued estimates for Syros Pharmaceuticals’ Q2 2018 earnings at ($0.51) EPS, Q3 2018 earnings at ($0.53) EPS, Q4 2018 earnings at ($0.59) EPS, FY2018 earnings at ($1.81) EPS, FY2019 earnings at ($2.28) EPS, FY2020 earnings at ($1.19) EPS, FY2021 earnings at $1.49 EPS and FY2022 earnings at $3.22 EPS.

How to Become a New Pot Stock Millionaire

Several other brokerages have also recently issued reports on SYRS. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Monday, December 11th. Zacks Investment Research lowered Syros Pharmaceuticals from a “buy” rating to a “hold” rating and set a $12.00 target price on the stock. in a research report on Saturday, January 20th. Wedbush reaffirmed an “outperform” rating and issued a $13.00 target price (up from $11.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, March 13th. BidaskClub raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 10th. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $10.00 target price on shares of Syros Pharmaceuticals in a research report on Thursday, December 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $21.13.

SYRS traded up $0.03 during trading hours on Thursday, hitting $12.43. 148,091 shares of the stock were exchanged, compared to its average volume of 184,092. Syros Pharmaceuticals has a 12 month low of $6.30 and a 12 month high of $24.38. The stock has a market capitalization of $400.17, a PE ratio of -5.84 and a beta of -2.83.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Monday, March 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.01).

Several institutional investors and hedge funds have recently modified their holdings of SYRS. ARK Investment Management LLC increased its holdings in shares of Syros Pharmaceuticals by 519.7% during the fourth quarter. ARK Investment Management LLC now owns 834,757 shares of the company’s stock valued at $8,122,000 after purchasing an additional 700,058 shares during the period. Vanguard Group Inc. increased its holdings in shares of Syros Pharmaceuticals by 189.6% during the second quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after purchasing an additional 250,507 shares during the period. Candriam Luxembourg S.C.A. acquired a new position in shares of Syros Pharmaceuticals during the third quarter valued at $1,766,000. State Street Corp increased its holdings in shares of Syros Pharmaceuticals by 176.7% during the second quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after purchasing an additional 108,250 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of Syros Pharmaceuticals during the third quarter valued at $975,000. 49.33% of the stock is currently owned by institutional investors.

In related news, Director Srinivas Akkaraju bought 209,424 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were purchased at an average cost of $9.55 per share, with a total value of $1,999,999.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 33.60% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Oppenheimer Comments on Syros Pharmaceuticals’ Q1 2018 Earnings (SYRS)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/syros-pharmaceuticals-forecasted-to-earn-q1-2018-earnings-of-0-17-per-share-syrs.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply